CRISPR Therapeutics Proposes Changes to the Board of Directors

NEXT STORY
Mesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019
PREV STORY
Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

author_avatar
NASDAQ Market News

TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS

author_avatar
NASDAQ Market News

Biocartis Group NV: Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presented at ESMO congress

    PRESS RELEASE: 19 October 2018, 07:00 CEST Studies on Idylla(TM) MSI and ...

author_avatar
NASDAQ Market News